Purpose
This Project aims at establishing a current Good Manufacturing Practices (cGMP)-compliant platform to manufacture clinical grade lentiviral vectors (including production, purification and quality control) at the Centre of Excellence for Cellular Therapy (CETC) of Hôpital Maisonneuve-Rosemont. It builds on the capacity of the CETC, the only fully operational cGMP-compliant cell therapy facility in Canada, to generate viral vectors of clinical and commercial grade at the 50L scale.
Centre for Commercialization of Cancer Immunotherapy × Unknown
4 grants totalling $3.7M
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
1,000 grants totalling $348.9M
Related Grants
| Recipient | Amount | Program |
|---|---|---|
| Quantum Valley Ideas Laboratories | $1.2M | Collaborative Science, Technology and In... |
| Mitacs inc. | $1.0M | Collaborative Science, Technology and In... |
| Centre for Commercialization of Cancer Immunotherapy | $1.0M | Collaborative Science, Technology and In... |
| Mitacs inc. | $1.0M | Collaborative Science, Technology and In... |
| Centre for Commercialization of Cancer Immunotherapy | $1.0M | Collaborative Science, Technology and In... |